Johnson & Johnson Says One-Shot Vaccine is 66% Effective Against Moderate to Severe COVID
Friday, January 29, 2021
Johnson & Johnson announced Friday that its single-shot coronavirus vaccine was 66% effective in protecting against moderate to severe COVID-19 disease in Phase 3 trials, which was comprised of nearly 44,000 participants across eight countries.
“Johnson & Johnson embarked on the global effort to combat the COVID-19 pandemic a year ago, and has brought the full force of our capabilities, as well as tremendous public-private partnerships, to enable the development of a single-shot vaccine. Our goal all along has been to create a simple, effective solution for the largest number of people possible, and to have maximum impact to help end the pandemic,” said Alex Gorsky, Chairman, Board of Directors and Chief Executive Officer, Johnson & Johnson, in the company's release.
GET THE LATEST BREAKING NEWS HERE -- SIGN UP FOR GOLOCAL FREE DAILY EBLAST
"The vaccine was 72% effective in the U.S., but only 57% effective in South Africa, where a more contagious variant has been spreading. It prevented 85% of severe infections and 100% of hospitalizations and deaths, according to the company."
This week, the United States Centers for Disease Control and Prevention announced Thursday that it is aware that the first US documented cases of the B 1.351 variant of SARS-CoV-2, which was first detected in South Africa, have been identified in South Carolina.
"The J&J vaccine turns in a fantastic result. We now have 3 highly effective vaccines. This vaccine showed sustained (and increasing!) immune protection over time, perhaps from a robust early induction of memory immune cells (CD4 and CD8)," tweeted former FDA commissioner Scott Gottlieb.
Efficacy in Focus, and FDA Approval
The vaccine is not as effective as some of its two-dose competitors -- the Johnson and Johnson vaccine results in development of neutralizing antibodies, is long-lasting and doesn’t require freezing like Moderna and Pfizer-BioNTech’s shots.
The vaccine can be stored at refrigerator temperatures for three months.
The company said it will file for emergency use authorization from the FDA within a week. The U.S. has purchased 100 million vaccine doses from J&J.
Related Articles
- Uber CEO & Brown Grad Tells Governors Company Wants Drivers to Get Vaccine Quickly, Easily & Free
- RI House COVID-19 Vaccine Task Force to Discuss Vaccine Distribution with CVS at 3 PM—Watch LIVE
- FDA Authorizes Pfizer’s Coronavirus Vaccine for Emergency Use
- RI Hospitals Begin Receiving Coronavirus Vaccine—Now Authorized to Vaccinate Frontline Workers
- Raimondo Claims Trump Short-Changed RI on Vaccine - 36% Decrease in Week Two
- Rhode Island Department of Health Warns of Vaccine Phishing Scam
- Pfizer Tells U.S. Supply of Vaccine Will Be Limited and Late, According to Reports
- Shekarchi Appoints House Task Force for COVID-19 Vaccine, Dr. Fine to Testify
- What RIers Need to Know About Vaccines: Who Will Manage Distribution, When, and Safety Concerns
- United Kingdom First Country to Approve Use of Pfizer Vaccine - Vaccinations to Begin Next Week
- Supply Chain Issues Cause Pfizer to Slash 2020 COVID-19 Vaccine Target, According to Reports
- Confusion and Finger Pointing Hits Coronavirus Vaccine Rollout, Impacting RI
- FDA Authorizes Moderna Coronavirus Vaccine for Emergency Use
- GoLocal Daily RI Vaccination Update: In NY, Seniors Quit Novavax Vaccine Trial and UK Races Past US
- GoLocal Daily RI Vaccination Update: MA Announces 65+ a Priority for Vaccine, No Word in RI
- GoLocal Daily RI Vaccination Update: RI Continues to Fall Behind in Vaccine Administration
- MA Gov. Baker’s Administration Announces Vaccine Appointment Bookings for Individuals 75+
- RIers 65+ Won’t Be Able to Schedule Vaccine Appointments Until Mid-February at Earliest
- EDITORIAL: RI Insiders Pushed Most Vulnerable Out of Way to Get Vaccine, Anything Lower?
- GoLocal Daily RI Vaccination Update: RI Has Utilized 44% of Its Vaccine, According to CDC
- VIDEO: Biden Receives First Dose of COVID-19 Vaccine on Camera
- RI Legislative Black & Latino Caucus Seeks COVID-19 Vaccine Priority for Communities of Color
- UK Approves Use of AstraZeneca Vaccine for Coronavirus
- AARP Calling for More “Clarity” on Vaccine Availability for Seniors